Infusyn Therapeutics, LLC, based in Hackettstown, NJ (USA), manufactures and markets the Prometra II® pump, the most sophisticated and precise implantable, fully-programmable drug delivery pump on the market. Prometra is approved by the US FDA for intrathecal delivery of opioids for the treatment of pain and baclofen for the treatment of spasticity.  InBrain utilized the Prometra II® pump for intracerebroventricular infusion of A-dopamine in the DIVE I clinical trial conducted between 2020 and 2025. Infusyn is also developing Prometra with its partners in oncology, CNS and cardio-pulmonary indications where precision dosing is crucial for improved efficacy and better patient outcomes.

Visit website

InBrain Pharma is a spin-off of the University of Lille, born out of academic and scientific excellence. InBrain Pharma works closely with the Lille Neuroscience & Cognition Research Center (LilNCog – INSERM CHU Lille- ULille), renowned for its multidisciplinary expertise in fundamental, clinical, and translational neuroscience. High-level scientific expertise, cutting-edge research infrastructure and an academic ecosystem that stimulates innovation in the field of brain health are made accessible through this proximity.

Visit website

A-dopamine for advanced Parkinson’s disease management : a medical innovation born at Lille University Hospital (CHU de Lille)

The A-dopamine project was initiated at CHU de Lille thanks to the work of two renowned neurology specialists, Prof. David Devos and Prof. Caroline Moreau. Together, they developed a new therapeutic approach protected by two patents, for which CHU de Lille is co‑owner.
To accelerate its development, CHU de Lille authorized the two researchers to co‑found the start‑up IBP, where they contribute their scientific expertise.

A public–private partnership to advance research for the benefit of patients

InBrain Pharma and CHU de Lille worked hand-in-hand to carry out the DIVE‑I monocentric clinical trial, conducted within the neurology department of the hospital.

In this context:

• CHU de Lille handled all regulatory procedures required to launch the study.
• It ensured daily operational oversight, including monitoring, data management, and budget follow‑up.
• The investigational drug, A‑dopamine, was developed and manufactured at CHU de Lille, in connection with the two patents underlying the DIVE technology.
• CHU teams also performed the statistical analyses necessary to interpret the results.

A shared ambition

This partnership between a major healthcare institution and an innovative young company demonstrates how medical expertise and entrepreneurial agility can complement each other to accelerate the availability of new solutions for patients.

Visit website